로딩 중…
지수 로딩 중…
큐라클
365270· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩14,290-0.90%
2026-06-19
Price Chart
큐라클+187.99%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 315.41B KRW |
| Revenue | 7.1M KRW |
| Net Income | -3.70B KRW |
| Total Assets | 55.20B KRW |
| Net Assets | 41.62B KRW |
| Employees | 32 |
| Value | |
| P/B | 7.58x |
| FCF Yield | -4.27% |
| Profitability | |
| ROE | -8.89% |
| ROA | -6.70% |
| Op. Margin | -223249.99% |
| Revenue Growth | -99.56% |
| Financial Health | |
| Debt Ratio | 132.63% |
| Total Debt | 14.77B KRW |
| FCF | -13.45B KRW |
| Cash | 5.05B KRW |
| Current Ratio | 2.10x |
| Performance | |
| 1Y Return | 187.99% |
| 1M Return | 9.00% |
| From 52W High | -31.13% |
| 1Y MDD | -44.19% |
| Trading | |
| Volume | 369,422 shares |
| Foreign Own. | 1.57% |
| Per Share | |
| EPS | -913 KRW |
| BPS | 1,898 KRW |
Company Info
Established in 2016, this company is a specialized bio-venture focusing on research and development of therapeutics for endothelial dysfunction, specially listed on KOSDAQ in 2021. It builds an innovative new drug pipeline and conducts research and development based on its proprietary new drug development platforms, Solvadis and Eagles. In 2024, Rivasterat demonstrated vision improvement in a US Phase 2a clinical trial, while CU01 is expanding its portfolio through joint research and development and completion of domestic Phase 2b patient recruitment in 2025. Curacle, established in 2016, is headquartered in Seoul Metropolitan City, Seocho-gu.